Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Intraocular Melanoma, Melanoma (Skin)
About this trial
This is an interventional treatment trial for Intraocular Melanoma focused on measuring stage III melanoma, stage IV melanoma, recurrent melanoma, recurrent intraocular melanoma, iris melanoma, extraocular extension melanoma, ciliary body and choroid melanoma, medium/large size
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of melanoma Unresectable stage III or IV disease Mucosal or ocular disease allowed Positive HLA-A1, -A2, or -A3 expression PATIENT CHARACTERISTICS: Age 12 and over Performance status ECOG 0-1 Life expectancy Not specified Hematopoietic Absolute neutrophil count > 1,000/mm^3 Platelet count > 100,000/mm^3 Hemoglobin > 9 g/dL Hepatic Liver function tests ≤ 2.5 times upper limit of normal (ULN) Renal Creatinine ≤ 1.5 times ULN Cardiovascular No New York Heart Association class III or IV heart disease Other Weight ≥ 100 pounds Not pregnant or nursing No other malignancy within the past 5 years except squamous cell or basal cell skin cancer without known metastasis, carcinoma in situ of the breast, or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy No prior vaccination with any of the peptides used in this protocol More than 1 year since prior melanoma vaccine therapy More than 4 weeks since prior immunotherapy More than 4 weeks since prior growth factors More than 4 weeks since prior allergy shots Chemotherapy More than 4 weeks since prior chemotherapy Endocrine therapy More than 4 weeks since prior steroid therapy Radiotherapy More than 4 weeks since prior radiotherapy Surgery Prior tumor resection allowed
Sites / Locations
- Cancer Center at the University of Virginia